Merz Aesthetics Invests in Regenerative Aesthetics Innovation, Leading Series A Funding of Acorn Biolabs

January 31, 2024
Merz Aesthetics

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has made an investment in Acorn Biolabs by leading its Series A funding round. Acorn Biolabs is a personalized regenerative medicine company with offices in Toronto, Canada and Los Angeles. Acorn Biolabs offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a client’s own cells. Terms were not disclosed.

“Merz Aesthetics is at the forefront of the emerging field of regenerative aesthetics, which seeks to stimulate the body’s own systems to repair and restore the structure and integrity of aging skin. We are looking to invest in opportunities that lie at the intersection of regenerative aesthetics and personalized medicine and our investment in Acorn Biolabs directly aligns with this strategy,” said Jon Parrish, PhD, chief corporate development officer at Merz Aesthetics.

Read more at Merz Aesthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • CGI Digital Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Kentucky Rules Do Not Allow Compounding of Six Peptides Despite HHS Peptide Enforcement Policy
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • Injectable PDGF Enters New Aesthetic Trials for Facial Skin Quality and Infraorbital Hollows